Science

This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.

Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.

Join BenevolentAI’s CEO Joanna Shields at Wired Health where she will be speaking about forging new frontiers in drug discovery by uniting human and artificial intelligence

Join BenevolentAI’s Chief Scientific Officer at Cambridge Science Festival where she will be speaking about Data science, AI and their potential to transform the discovery and development of medicines.

Join Jackie Hunter at the LSX World Congress where she will discuss AI in drug discovery and development in a panel alongside leaders from Atomwise, Arctoris, Sensyne Health.

Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.